Brokers Set Expectations for ABUS FY2029 Earnings

Arbutus Biopharma Co. (NASDAQ:ABUS) – Investment analysts at HC Wainwright issued their FY2029 earnings per share estimates for Arbutus Biopharma in a research note issued on Wednesday, February 26th. HC Wainwright analyst E. Arce anticipates that the biopharmaceutical company will earn $0.29 per share for the year. HC Wainwright has a “Buy” rating and a $5.00 price target on the stock. The consensus estimate for Arbutus Biopharma’s current full-year earnings is ($0.39) per share.

Other equities analysts have also issued research reports about the stock. StockNews.com lowered shares of Arbutus Biopharma from a “hold” rating to a “sell” rating in a report on Tuesday. JMP Securities lifted their target price on shares of Arbutus Biopharma to $5.00 and gave the company a “buy” rating in a report on Wednesday, November 6th. Finally, Chardan Capital restated a “buy” rating and set a $5.00 price objective (up previously from $4.50) on shares of Arbutus Biopharma in a research note on Wednesday, November 20th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, Arbutus Biopharma currently has an average rating of “Moderate Buy” and a consensus target price of $5.50.

Arbutus Biopharma Trading Down 2.0 %

Shares of NASDAQ:ABUS opened at $3.37 on Thursday. The firm has a market cap of $638.58 million, a price-to-earnings ratio of -7.84 and a beta of 1.78. Arbutus Biopharma has a 12-month low of $2.30 and a 12-month high of $4.72. The stock’s 50-day moving average price is $3.31 and its two-hundred day moving average price is $3.66.

Hedge Funds Weigh In On Arbutus Biopharma

Several large investors have recently bought and sold shares of the stock. Two Seas Capital LP lifted its position in Arbutus Biopharma by 4.2% in the fourth quarter. Two Seas Capital LP now owns 8,740,956 shares of the biopharmaceutical company’s stock worth $28,583,000 after purchasing an additional 353,568 shares during the period. Whitefort Capital Management LP raised its stake in shares of Arbutus Biopharma by 2.9% in the 4th quarter. Whitefort Capital Management LP now owns 13,241,916 shares of the biopharmaceutical company’s stock worth $43,301,000 after buying an additional 373,949 shares in the last quarter. Woodline Partners LP raised its stake in shares of Arbutus Biopharma by 45.4% in the 4th quarter. Woodline Partners LP now owns 971,628 shares of the biopharmaceutical company’s stock worth $3,177,000 after buying an additional 303,475 shares in the last quarter. Saba Capital Management L.P. lifted its holdings in shares of Arbutus Biopharma by 31.3% in the fourth quarter. Saba Capital Management L.P. now owns 887,993 shares of the biopharmaceutical company’s stock valued at $2,904,000 after buying an additional 211,566 shares during the period. Finally, Rafferty Asset Management LLC boosted its stake in Arbutus Biopharma by 27.6% during the fourth quarter. Rafferty Asset Management LLC now owns 146,803 shares of the biopharmaceutical company’s stock valued at $480,000 after buying an additional 31,782 shares in the last quarter. Institutional investors and hedge funds own 43.79% of the company’s stock.

About Arbutus Biopharma

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.